A Phase 3 interventional study of dronedarone (SR33589) and amiodarone in Atrial Fibrillation, sponsored by Sanofi. Completed at 23 sites in 23 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2010-02-18.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies testing dronedarone in Atrial Fibrillation — 2 open to participants now, 2 under way, none of them phase 3. Dronedarone · Atrial Fibrillation.
Among the 26 studies testing dronedarone in Atrial Fibrillation, this one is the 6th largest by enrollment, is the only one that started in 2007, is one of 7 in phase 3, and was the 4th registered.
4,011 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.
Browse Atrial Fibrillation studies →2 of the 26 studies testing dronedarone in Atrial Fibrillation are open now, in 2 countries. Recruiting first, the newest first:
Shanghai East Hospital · Sites in China
Ages 18–80
Inha University Hospital · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Dronedarone: first FDA approval 2009 (MULTAQ), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 611 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 8 · Phase 4 11
First in 2001; this study’s year is marked. 1 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 504 is above the median of 150 across 2,477 interventional studies indexed under Atrial Fibrillation.
Median enrollment 164 across the 26 interventional studies. Of the 20 that completed or were terminated, 8 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 26 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
23 studies in Atrial Fibrillation by Sanofi: none open now, none under way, none of them phase 3. Of 23 finished, 7 (30%) have results posted.
Among the 23 studies in Atrial Fibrillation by Sanofi, this one is the 11th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2007, is one of 11 in phase 3, and was the 10th registered.
Sanofi’s Atrial Fibrillation studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 26 studies testing dronedarone in Atrial Fibrillation, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 23 in Atrial Fibrillation:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The objective of this study is to compare the efficacy and safety of dronedarone to that of amiodarone for the treatment of patients with atrial fibrillation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information are not intended to contain all the considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
dronedarone 400mg tablets administered twice a day (bid) and matching over-encapsulated tablets of placebo of amiodarone 200mg
Drug: dronedarone (SR33589)
over-encapsulated tablets of amiodarone 200mg (600mg daily for 28 days then 200mg daily) administered once daily (od) and matching placebo of dronedarone 400mg tablets
Drug: amiodarone
oral administration
Also known as: Multaq®
oral administration
Treatment Failure
The primary event is the treatment failure defined as the first recurrence of atrial fibrillation or premature study drug discontinuation for intolerance or lack of efficacy according to the investigator judgement. The primary efficacy analysis is performed on the time from first study drug intake to this primary event. The "Measured Values" table below presents the numbers of patients with the event at the end of the study period.
Time frame: minimum study duration is 6 months (+10 days); maximum is 15 months
Occurrence of the Main Safety Endpoint (MSE) Defined as Thyroid, Hepatic, Pulmonary, Neurological, Skin, Eye, or Gastrointestinal Specific Treatment Emergent Events or Premature Study Drug Discontinuation Following Any Adverse Event
The considered event is the occurrence of the MSE defined as thyroid, hepatic, pulmonary, neurological, skin, eye, or gastrointestinal specific treatment emergent events or premature study drug discontinuation following any adverse event (AE), whichever comes first. The analysis is performed on the time from first study drug intake to this event. The "Measured Values" table below presents the numbers of patients with the event at the end of the study period.
Time frame: minimum study duration is 6 months (+10 days); maximum is 15 months
Occurrence of the MSE Excluding Gastrointestinal Specific Treatment Emergent Events Defined as Diarrhoea, Nausea, Vomiting
The considered event is the occurrence of the MSE excluding gastrointestinal specific treatment emergent events defined as diarrhoea, nausea, vomiting. The analysis is performed on the time from first study drug intake to this event. The "Measured Values" table below presents the numbers of patients with the event at the end of the study period.
Time frame: minimum study duration is 6 months (+10 days); maximum is 15 months
Enrollment of patients started on June 12, 2007 and was completed on October 3, 2008. The study was conducted in 112 centers in 23 countries. Minimum duration of treatment was 6 months. Minimum duration of observation was last patient's randomization plus 190 days.
| Milestone | Dronedarone 400mg Bid | Amiodarone 600mg/200mg od |
|---|---|---|
| Started | 249 | 255 |
| Completed | 153 | 186 |
| Not completed | 96 | 69 |
| Withdrew: Lack of efficacy | 53 | 14 |
| Withdrew: Adverse event | 32 | 45 |
| Withdrew: Poor compliance | 6 | 2 |
| Withdrew: Not coded/ not pre-specified | 5 | 8 |
The primary event is the treatment failure defined as the first recurrence of atrial fibrillation or premature study drug discontinuation for intolerance or lack of efficacy according to the investigator judgement. The primary efficacy analysis is performed on the time from first study drug intake to this primary event. The "Measured Values" table below presents the numbers of patients with the event at the end of the study period.
| participants | Dronedarone 400mg Bid | Amiodarone 600mg/200mg od |
|---|---|---|
| Treatment Failure | 184 (37.0 to 45.0) | 141 (99.0 to 275.0) |
The considered event is the occurrence of the MSE defined as thyroid, hepatic, pulmonary, neurological, skin, eye, or gastrointestinal specific treatment emergent events or premature study drug discontinuation following any adverse event (AE), whichever comes first. The analysis is performed on the time from first study drug intake to this event. The "Measured Values" table below presents the numbers of patients with the event at the end of the study period.
| participants | Dronedarone 400mg Bid | Amiodarone 600mg/200mg od |
|---|---|---|
| Occurrence of the Main Safety Endpoint (MSE) Defined as Thyroid, Hepatic, Pulmonary, Neurological, Skin, Eye, or Gastrointestinal Specific Treatment Emergent Events or Premature Study Drug Discontinuation Following Any Adverse Event | 83 | 107 |
The considered event is the occurrence of the MSE excluding gastrointestinal specific treatment emergent events defined as diarrhoea, nausea, vomiting. The analysis is performed on the time from first study drug intake to this event. The "Measured Values" table below presents the numbers of patients with the event at the end of the study period.
| participants | Dronedarone 400mg Bid | Amiodarone 600mg/200mg od |
|---|---|---|
| Occurrence of the MSE Excluding Gastrointestinal Specific Treatment Emergent Events Defined as Diarrhoea, Nausea, Vomiting | 61 | 99 |
Collected over From first to last study drug intake +10 days i.e. end of the study.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dronedarone 400mg Bid | — | 34/249 (13.7%) | 146/249 (58.6%) |
| Amiodarone 600mg/200mg od | — | 37/255 (14.5%) | 165/255 (64.7%) |
| Event | Dronedarone 400mg Bid | Amiodarone 600mg/200mg od |
|---|---|---|
| Cardiac failureCardiac disorders | 6/249 | 1/255 |
| Cardiac failure congestiveCardiac disorders | 1/249 | 6/255 |
| Therapeutic agent toxicityInjury, poisoning and procedural complications | 1/249 | 3/255 |
| PneumoniaInfections and infestations | 2/249 | 0/255 |
| BradycardiaCardiac disorders | 1/249 | 2/255 |
| BronchitisInfections and infestations | 0/249 | 2/255 |
| SyncopeNervous system disorders | 0/249 | 2/255 |
| Accidental overdoseInjury, poisoning and procedural complications | 0/249 | 2/255 |
| International normalised ratio increasedInvestigations | 0/249 | 2/255 |
| Angina pectorisCardiac disorders | 1/249 | 1/255 |
| Event | Dronedarone 400mg Bid | Amiodarone 600mg/200mg od |
|---|---|---|
| Any Gastrointestinal disordersGastrointestinal disorders | 54/249 | 44/255 |
| Any Nervous system disordersNervous system disorders | 17/249 | 39/255 |
| Any Cardiac disordersCardiac disorders | 21/249 | 36/255 |
| Any Infections and infestationsInfections and infestations | 35/249 | 35/255 |
| Any InvestigationsInvestigations | 33/249 | 35/255 |
| Any General disorders and administration site conditionsGeneral disorders | 14/249 | 26/255 |
| DiarrhoeaGastrointestinal disorders | 23/249 | 8/255 |
| Any Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders | 18/249 | 23/255 |
| Any Vascular disordersVascular disorders | 9/249 | 23/255 |
| Any Psychiatric disordersPsychiatric disorders | 6/249 | 23/255 |
| Age, Customized(participants) | Dronedarone 400mg Bid | Amiodarone 600mg/200mg od | Total |
|---|---|---|---|
| 18 to < 65 years | 125 | 138 | 263 |
| 65 to < 75 years | 76 | 70 | 146 |
| >= 75 years | 48 | 47 | 95 |
| Age Continuous(years) | Dronedarone 400mg Bid | Amiodarone 600mg/200mg od | Total |
|---|---|---|---|
| Mean | 64.4 ± 10.8 | 63.7 ± 10.6 | 64.0 ± 10.7 |
| Sex: Female, Male(Participants) | Dronedarone 400mg Bid | Amiodarone 600mg/200mg od | Total |
|---|---|---|---|
| Female | 73 | 73 | 146 |
| Male | 176 | 182 | 358 |
The record gives a start of Jun 2007, a primary completion of Oct 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2009, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dronedarone